Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population / Schirripa M.; Nappo F.; Cremolini C.; Salvatore L.; Rossini D.; Bensi M.; Businello G.; Pietrantonio F.; Randon G.; Fuca G.; Boccaccino A.; Bergamo F.; Lonardi S.; Dei Tos A.P.; Fassan M.; Loupakis F.. - In: CLINICAL COLORECTAL CANCER. - ISSN 1533-0028. - ELETTRONICO. - 19:(2020), pp. 219-225. [10.1016/j.clcc.2020.04.009]
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Rossini D.;
2020
Abstract
Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
